Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy
The early development of autonomic dysfunction and nOH is an independent predictive factor for shorter survival in ATTRv. Autonomic testing is a valuable biomarker to capture disease progression. Prospective studies need to confirm the benefit of DMT on autonomic dysfunction.
Authors
- Mary M. Reilly (ORCID: https://orcid.org/0000-0003-0686-905X)
- Domenico Abelardo (ORCID: https://orcid.org/0009-0000-9676-3675)
- Patricia McNamara (ORCID: https://orcid.org/0000-0002-3011-0177)
- Valeria Iodice (ORCID: https://orcid.org/0000-0001-7400-5611)
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Carol Jane Whelan (ORCID: https://orcid.org/0000-0002-9743-9567)
- Giacomo Chiaro
- Laura Sander (ORCID: https://orcid.org/0000-0002-9191-4005)
- A de Torrenté (ORCID: https://orcid.org/0000-0002-0585-8351)
- Gordon Ingle
- Laura Watson
- C. J. Mathias
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
- Magna Graecia University (IT)
- Amyloidosis Foundation (US)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- University of Palermo (IT)
Publication Details
- Journal
- Amyloid
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1080/13506129.2025.2494657
- Citations
- 3
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.42